NDAORALTABLET
Approved
Jul 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LO/OVRAL FE (ethinyl estradiol; levonorgestrel; ferrous fumarate) by Cadence Neuroscience is ovulation. First approved in 1979.
Drug data last refreshed 43m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL FE is an oral contraceptive tablet containing ethinyl estradiol and levonorgestrel, with added ferrous fumarate for iron supplementation. It prevents pregnancy by suppressing ovulation and is indicated for contraception in women of reproductive age. The ferrous fumarate component addresses iron loss during menstruation, offering dual therapeutic benefit.
LOE Approaching
LOE approaching indicates declining team investment; career growth on this brand will be limited as resources shift to newer contraceptive portfolios.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LO/OVRAL FE offers limited career growth due to LOE approaching and zero linked job openings. This role suits professionals seeking stability in a mature product management environment rather than high-growth opportunities.
Brand ManagerField Sales Representative
Worked on LO/OVRAL FE at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.